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itive control (Mutation Detection Enhancement gel sys-
tem; FMC BioProducts). Patient DNA mixed with equal
amounts of DF311 control DNA showed the same het-
eroduplex pattern as did either the patient DNA sample
or the DF311 heterozygote DNA sample alone, sug-
gesting that these abnormal alleles were identical. DNA
sequencing using the ABI 377 nucleic acid sequencer
subsequently confirmed this sequence change to be the
DF311 mutation in heterozygous form.
Maternal cell contamination was ruled out by MCT-
118 genotyping. The father of the fetus was not available
for testing, and no other CF mutation or abnormal het-
eroduplex pattern was detected in the fetal sample. Be-
cause of the presence of the Dandy-Walker malforma-
tion, and prior to the CF results being provided to the
patient, the patient elected to terminate the pregnancy.
An autopsy was not performed, and fetal tissue was not
available for confirmation of the amniocentesis results.
DF311 was first reported in a 2-year-old boy with a
positive albumin-meconium test at birth and with re-
peatedly elevated sweat tests by age 4 mo (Meitinger et
al. 1993). His other mutation is DF508. Prophylactic
treatment with both pancreatic enzymes and mucolytic
agents to deter lung disease has prevented the onset of
either pulmonary or pancreatic symptoms in his first 6
years. The authors of that study did not identify any
other individuals with this mutation, after screening an
additional 205 CF chromosomes by SSCP (T. Meitinger,
personal communication). This patient is of Bavarian
Caucasian descent, and his pancreatic disease is distinct
from that of the patient seen at the University of North
Carolina in Chapel Hill (UNC), obscuring any corre-
lation between DF311 and a particular phenotype. Ap-
parent clinical dissimilarities among these three patients
might be attributable to undefined aspects of either the
genetic background or the environment, but low num-
bers prevent the drawing of conclusions along racial or
other lines. Interestingly, the two individuals whom we
describe, as well as the index case, each harbor a distinct
DF311-associated haplotype (1 1 2, 1 2 2, and 2 1 2)
defined by the flanking markers, XV2c-KM19-J3.11,
suggesting that this mutation has occurred more than
once. The multiple origins of DF311 suggest that it might
be found on additional chromosomes, but this would
not be limited to African American patients.
DF311 has thus been identified in two individuals of
African American ancestry. In this racial group, this mu-
tation appears to be more common than any CFTR mu-
tation except DF508, compared with other alleles also
identified in Caucasians. Among the 23 African Amer-
ican CF patients genotyped at UNC, the inclusion of
DF311 increased total mutation-detection rates by ˜2%.
On the basis of the criteria established by Macek et al.,
we feel that molecular diagnostic laboratories should
consider the inclusion of DF311 in the development of
CF mutation-testing panels tailored to African
Americans.
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mtDNA Mutations That Cause Optic Neuropathy:
How Do We Know?
To the Editor:
Leber hereditary optic neuropathy (LHON) is an inher-
ited form of bilateral optic atrophy in which the primary
etiological factor is a mutation in the mitochondrial ge-
nome (mtDNA) (reviewed in Johns 1994; Riordan-Eva
et al. 1995; Nikoskelainen et al. 1996; Howell 1997).
Wallace et al. (1988) were the first group to identify a
LHON mutation, when they showed that a high pro-
portion of LHON families carried a mutation, at nucle-
otide 11778, that results in the substitution of histidine
for the highly conserved arginine at amino acid po-
sition 340 of the ND4 subunit of complex I
(NADH–ubiquinone oxidoreductase). The 11778 mu-
tation is found in 50%–70% of all LHON pedigrees
(e.g., see Mackey et al. 1996). Since the study by Wallace
et al. (1988), hundreds of LHON patients from around
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Figure 1 Matrilineal pedigree of 14482 LHON family. The blackened symbols denote those individuals who are affected with optic
neuropathy, whereas the unblackened symbols denote those of either normal or unknown ophthalmological status. An “N”a symbol indicates
that the individual has been examined by one of the authors (D.A.M.) and has been found to be devoid of any signs of optic neuropathy. Note
the high frequency of consanguineous marriages in this family (indicated by double lines). Accurate genealogical information for this complicated
pedigree was difficult to obtain, especially for the earlier generations.
the world have been analyzed, to identify other LHON
mtDNA mutations. There is now a consensus that tran-
sitions at nucleotides 3460 and 14484 (ND1/A52T and
ND6/M64V, respectively) are also pathogenic LHON
mutations (reviewed in Brown and Wallace 1994; Johns
1994; Howell 1997). These three LHON mutations ac-
count for 195% of the multigeneration LHON pedigrees
of northern European descent (Mackey et al. 1996), and
each of these mutations has arisen multiple times within
the human population (Brown et al. 1995; Howell et al.
1995).
Beyond this broad agreement about the 3460, 11778,
and 14484 mutations, it is not yet clear how many other
mtDNA mutations have an etiological or pathogenic role
in LHON. Some investigators maintain that there are
numerous mutations associated with LHON and that
these can have primary, secondary, or intermediate levels
of pathogenicity (e.g., Brown and Wallace [1994] list a
total of 16 mutations). The identification of LHON mu-
tations has been controversial, in large part because there
is no single “proof,” genetic or biochemical, that has
emerged (see the discussion in the work of Howell
[1994a, 1994b, 1997]). Uncertainty accompanies, in
particular, the analysis of singleton patients or small fam-
ilies with a LHON-like optic atrophy, because maternal
inheritance—the unambiguous genetic characteristic of
LHON—is not present. Furthermore, the human mito-
chondrial genome has a high rate of mutation (e.g., see
Howell et al. 1996), and pathogenic muta-
tions—particularly those that are rare and/or that have
not been described previously—are difficult to identify,
because they are “buried” within a background of be-
nign polymorphisms.
In this report, we present evidence for a rare mutation
in the mitochondrial ND6 gene of a Turkish matrilineal
pedigree in which several family members are affected
with bilateral optic atrophy. At the age of 18 years, fam-
ily member VIII-20 (fig. 1), who is the index case, ex-
perienced a loss of vision in his right eye (oculus dexter
[OD]), over the course of a few weeks in 1991. Within
2 wk of onset, the left eye (oculus sinister [OS]) also
became affected, and LHON was diagnosed, in Turkey,
at that time. This individual and his wife (who is also
his maternal first cousin; VIII-21 in fig. 1) subsequently
moved to Australia where, on examination in 1996, his
visual acuities were 6/60 OD and 3/60 OS. He had mod-
erate centrocecal scotomata and marked temporal pallor
of the optic disks. His wife’s visual acuity and ophthal-
mological examination were normal. The index case’s
maternal first cousin (VIII-23), who is also his wife’s
brother, experienced a loss of vision over a period of 4
mo in 1992, at the age of 22 years. On examination in
1997, his visual acuities were 2/60 OD and 1/60 OS.
He had moderate to severe centrocecal scotomata and
generalized pallor of the disks.
The index case’s mother-in-law (also a maternal rel-
ative; VII-26 in fig. 1) reported normal vision, with no
recollection of any vision problems, but examination
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revealed that she also had ophthalmological abnormal-
ities. Her visual acuities were 6/9 OD and 6/6 OS, but
her visual fields showed marked scotomata, and fun-
doscopic examination revealed bilateral optic atrophy
with pseudocupping of the disks. The remainder of the
family lives in Turkey, and further clinical information
is difficult to obtain. However, six male family members
have lost central vision, but they have reportedly recov-
ered vision to a significant extent, because they are now
capable of driving automobiles. None of those individ-
uals has been examined by an ophthalmologist. It has
recently been possible to examine other family members,
during a visit to Australia: the index case’s mother (VII-
24), his father (VII-25), his wife’s father (VI-10), his
sister (VIII-19), two of his aunts (VII-16 and VII-17),
and his cousin (VIII-14) have normal vision with no signs
of optic neuropathy. The optic neuropathy in this family
is thus fully consonant with LHON, and it differs from
other bilateral optic atrophies, such as juvenile-onset au-
tosomal dominant optic atrophy (e.g., see Brown et al.
1997; Johnson et al. 1997). In addition, the genealogical
results are not compatible with autosomal dominant op-
tic neuropathy, because the index case’s mother (VII-24)
and both of the latter’s parents had normal vision. The
optic neuropathy shows apparent maternal transmis-
sion, but there have been several consanguineous mar-
riages within the pedigree (not all are shown in fig. 1),
and there was the additional possibility of autosomal
recessive optic atrophy. However, several of the visually
affected family members (including the index case) had
fathers who were not related to the matrilineal pedigree
and who came from outside the village, a circumstance
that argues against an autosomal recessive etiology.
Nucleotide sequencing revealed that the mtDNA of
this family did not carry one of the three previously
identified LHON mutations—at nucleotides 3460,
11778, or 14484—or any of the other possible LHON
mutations (Brown and Wallace 1994). However, all eight
maternal relatives who were assayed carry, at nucleotide
14482, a C:G transversion that results in the substitution
of isoleucine for the methionine at amino acid residue
64 of the ND6 subunit of complex I, the same amino
acid residue that is altered by the 14484 primary LHON
mutation. Subsequently, we sequenced this region of the
mitochondrial ND6 gene from ∼200 normal controls,
non-LHON controls, optic atrophy patients with no
identified LHON mutation, and LHON family mem-
bers; none of them carried the 14482 mutation (data
not shown). In addition, a further 250 unrelated pa-
tients, who had a LHON-like bilateral optic neuropathy
but who lacked one of the three previously identified
pathogenic LHON mutations, were screened by dena-
turing-gradient gel electrophoresis. None of these pa-
tients carried the 14482 mutation. These data therefore
suggest that the 14482 mutation has arisen rarely within
the human population.
The second stage of the genetic analysis involved de-
termination of the nucleotide sequence of the entire mi-
tochondrial genome from one member of this LHON
family (VIII-21). To ensure the accuracy of the nucleotide
sequence, several fragments of the mtDNA of her af-
fected husband/maternal first cousin (VIII-20) were se-
quenced, and agreement was obtained in all instances.
A total of 25 sequence changes relative to the Cambridge
Reference Sequence (CRS) were determined: 20 transi-
tions, 4 transversions, and a 1-bp deletion (table 1). Six
sequence changes were found in the 12S and 16S rRNA
genes, and one mutation was found in a tRNA gene. Of
the 18 mutations in protein-encoding genes, 5 produced
amino acid changes (including that at nucleotide 14482),
whereas 13 were phenotypically silent. Therefore, if one
includes all mutations that produce amino acid changes
and those in rRNA and tRNA genes, there are a total
of 12 candidate mutations that could be pathogenic.
Although no mutations in tRNA or rRNA genes have
been identified in previous analyses of LHON patients,
we did not eliminate them at this stage, in order not to
bias the ultimate conclusions of the analysis. The basic
question, therefore, is the following: Is the 14482 mu-
tation the primary etiological factor that causes the optic
neuropathy in this matrilineal pedigree, or is it caused
by one or more of the other sequence changes that are
carried by the mtDNA?
Several of these candidate mutations could be effec-
tively eliminated, because a search of the MITOMAP
database (Wallace et al. 1995; Kogelnick et al. 1996)
revealed that they have been detected previously in pop-
ulation screening studies (see table 1). To confirm and
extend the results of database searching, comparative
sequence analyses of mtDNAs that are phylogenetically
related to the index lineage were also performed (Jun et
al. 1994; Brown et al. 1995; Howell et al. 1995; Hutchin
and Cortopassi 1997). As part of the analysis of the
14482 LHON family, we determined the nucleotide se-
quence of the 1.1-kb noncoding control region, or D-
loop (table 1). A search of our D-loop sequence database
(derived from ∼140 non-LHON and LHON pedigrees;
N. Howell, unpublished data) yielded five sequences that
were closely related; three of the DNA samples were
from normal controls, and two were from unrelated
11778 LHON families. An inspection of the sequence
of the 14482 mtDNA D-loop and of the D-loops in the
phylogenetically related sequences indicates that these
mitochondrial genomes are members of European hap-
logroup I (Torroni et al. 1994, 1996). The occurrence
of shared CRS changes confirms this relationship. Tor-
roni et al. (1994, 1996) found haplogroup I–specific re-
striction-site changes at map positions 1715, 4529,
8249, 10028, 10394, and 16389, whereas our sequenc-
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Table 1
mtDNA CRS Changes in the LHON Pedigree
Nucleotide
Positiona Gene
Nucleotide
Changea
Amino Acid
Changeb
1438c 12S A:G NA
1531 12S C:T NA
1719c 16S G:A NA
2173 16S C:G NA
2706c 16S A:G NA
3106/3107cd 16S C:del NA
3447c ND1 A:G Q47Q
4529c ND2 A:T T20T
6734 COX1 G:A M277M
8251c COX2 G:A G222G
8260 COX2 T:C F225F
8616 ATP6 G:T L30L
9966c COX3 G:A V254I
10034c tRNAglu T:C NA
10238c ND3 T:C I60I
10398c ND3 A:G T114A
10609 ND4L T:C M47T
11719c ND4 G:A G320G
12501c ND5 G:A M55M
12705c ND5 C:T I123I
12864 ND5 T:C R176R
13780c ND5 A:G I482V
14482e ND6 C:G M64I
15043c CTYB G:A G99G
15589 CTYB C:T L281L
a Based on the L-strand of the Cambridge Reference Sequence (An-
derson et al. 1981). Previous analyses have shown that the CRS con-
tains errors or rare polymorphisms at nucleotides 263, 750, 3423,
4769, 4985, 7028, 8860, 9559, 11335, 13702, 14199, 14272, 14365,
14368, and 15326 (e.g., see Howell et al. 1992; Jun et al. 1994). These
sequences changes were also found in this mtDNA. In addition to the
sequence changes in the coding region, the following changes were
found in the D-loop: 73/A:G, 199/T:C, 204/T:C, 250/T:C, 16129/G:
A, 16172/T:C, 16223/C:T, 16311/T:C, 16391/G:A, and 16519/T:C. In
addition, the C6 repeat that begins at nucleotide 568 expands unstably
to a length of 9–11 residues in members of the 14482 pedigree.
b The first letter is the amino acid residue encoded by the reference
sequence, whereas the second is the predicted residue encoded by the
mtDNA of the LHON pedigree. Note that most nucleotide changes
are phenotypically silent. The intervening number is the position within
the amino acid sequence of the relevant gene. NA  not applicable.
c Also observed within the population, as determined by a search
of the MITOMAP database (Wallace et al. 1995; Kogelnick et al.
1996).
d The CRS has a C-C doublet at nucleotides 3106 and 3107, whereas
the 14482 lineage has a deletion of one of these base pairs.
e Creates a new Sau3A restriction site. Nucleotide sequencing in-
dicates that the members of this matrilineal pedigree are homoplasmic
for the transversion but that this newly created site is relatively resistant
to Sau3A cleavage (data not shown). As a result, it appears erroneously
that these individuals are heteroplasmic, with 10%–20% of the 14482
wild-type allele, under standard restriction-endonuclease digestion
conditions.
ing analyses revealed substitutions at nucleotides 1719,
4529, 8251, 10034, 10398, and 16391, respectively, in
the mtDNA of the 14482 LHON family (table 1).
Of the 18 sequence changes in the 14482 lineage that
have been analyzed, 4 are carried only by this lineage,
including the transversion at nucleotide 14482, whereas
14 are carried by the other haplogroup I lineages (table
2) and/or have been identified previously as polymor-
phisms within the population (table 1). However, the
substitution mutations at nucleotides 10609 (ND4L/
M47T) and 14482 (ND6/M64I), the silent polymor-
phism at nucleotide 8260, and the rRNA sequence
change at nucleotide 1531 occur only in the 14482
lineage.
The ophthalmological presentation and its maternal
inheritance are strongly indicative of LHON in this mat-
rilineal pedigree. Although the analysis of this family
was complicated by several factors, including the rarity
of the 14482 mutation within the population, it can be
concluded that the transversion at nucleotide 14482 is
a rare LHON mutation, which is the primary etiological
cause of the ophthalmological disorder in this matrilin-
eal pedigree. We have substantial confidence in this con-
clusion, for the following reasons, although we distin-
guish “strong evidence” from “proof.”
1. The 14482 mutation (M64I) alters the same amino
acid residue that is affected by the well-established
14484 LHON mutation (M64V). Among the 3460,
11778, and 14484 primary LHON mutations, it is the
14484 mutation that is associated with a high frequency
of vision recovery (e.g., see Mackey and Howell 1992;
Johns 1994). The anecdotal evidence is particularly
striking, therefore, in that the 14482 family also presents
an optic atrophy in which there is recovery of vision.
2. The 14482 mutation affects an amino acid residue
within an apparent “hotspot” for optic neuropathy, the
mitochondrial ND6 gene. In addition to the 14484 pri-
mary LHON mutation, which is the second most prev-
alent LHON mutation (e.g., see Johns 1994; Howell et
al. 1996), Leo-Kottler et al. (1996) have recently iden-
tified a German LHON family that harbors a mutation
at nucleotide 14498 of the ND6 gene (Y59C). Further-
more, Shoffner et al. (1995) have found that a mutation
at nucleotide 14459 causes LHON plus dystonia
(A72V). Similarly, De Vries et al. (1996) have analyzed
a large Dutch family in which the LHON-like optic neu-
ropathy is associated with a spastic dystonia (and other
neurological abnormalities). They found two candidate
mutations, one in the ND4 gene (nucleotide 11696;
V396I) and one in the ND6 gene (nucleotide 14596;
I26M); either or both mutations may be the primary
etiological factor(s). Most recently, Wissinger et al.
(1997) have identified a singleton case of optic neurop-
athy who carries an ND6 mutation at nucleotide 14568
(G36S). The present results thus add support for an
emerging “picture” of ND6 mutations, in which they
tend to produce subtle amino acid substitutions at sites
(probably within a hydrophobic or transmembrane do-
main) that are only moderately conserved during evo-
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Table 2
Comparative Analysis of the 14482 Index-Case Mitochondrial Coding Region Sequence and Phylogenetically Related mtDNA Lineages
NUCLEOTIDE SITE
STATUS OF INDIVIDUALa
0544 0049 0057 0073 0117 0136
14482 ND6 / M64I      
1438 12S   NT   
1531 12S   NT   
1719 16S   NT   
2173 16S   NT   
2706 16S   NT   
3106 / 3107 16S   NT   
3447 ND1 / Q47Q      
4529b ND2/T20T   NT NT  NT
8251b COX2 / G222G      
8260 COX2 / F225F      
9966 COX3 / V254I      
10034b tRNAglu      
10238 ND3 / I60I      
10609 ND4 / M47T      
11719 ND4 / G320G      
12705 ND5 / I123I      
13780 ND5 / I482V      
a A plus sign () indicates that the sequence change is present, whereas a minus sign () indicates that it is absent (i.e., it is the CRS). NT
 not tested. 0544 is a member of 14482 lineage, whereas 0049, 0057, and 0136 are normal controls. 0073 and 0117 are independent 11778
LHON lineages.
b The presence of this sequence change had been suggested earlier by restriction-site assays of haplogroup I individuals (Torroni et al. 1994,
1996). However, our results indicate that the restriction-site data of Torroni et al. (1994, 1996) are erroneous in one instance: haplogroup I
mtDNAs gain an AluI site at position 10032 (in their system for designation of restriction sites), rather than at position 10028.
lution (e.g., see table 1 of Leo-Kottler et al. 1996). This
pattern suggests that some aspect of complex I function
is exquisitely sensitive to the structure of this putative
domain and that the structure is tightly constrained by
the interactions of multiple amino acid residues.
3. The 14482 mutation affects a subunit of complex
I, as do the three previously established primary muta-
tions. However, that logic also supports a possible eti-
ological role for the ND4 mutation at nucleotide 10609.
There is less precedent for an etiological role of the
rRNA mutation at nucleotide 1531, because there is no
evidence that rRNA mutations are associated with
LHON, although a mitochondrial 12S rRNA mutation
at nucleotide 1555 causes nonsyndromic deafness (e.g.,
see Hutchin and Cortopassi 1997, and references
therein).
There is a burgeoning interest in the possible role that
mtDNA mutations may play in etiologically more-com-
plex disorders, in which a clear-cut pattern of maternal
inheritance is lacking. For example, there has been con-
siderable effort expended to determine whether a mu-
tation at nucleotide 4336 of the mitochondrial tRNAgln
gene is preferentially associated with Alzheimer disease
(AD) patients, relative to normal controls (Shoffner et
al. 1993; Hutchin and Cortopassi 1995). The most re-
cent data argue against an etiological role (Tysoe et al.
1996; also see Hutchin and Cortopassi 1997). However,
the general question will persist, especially in light of
the reports that there is a preferential maternal trans-
mission of AD (Edland et al. 1996), a result compatible
with a mitochondrial genetic contribution. The results
presented here underscore the difficulties that can be
encountered in the investigation of the etiological role
of rare mtDNA mutations.
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Power, Mode of Inheritance, and Type I Error in Lod
Scores and Affecteds-Only Methods: Reply to
Kruglyak
To the Editor:
We had previously written a letter examining some of
the issues involved in comparing LOD scores versus af-
fecteds-only and other ‘‘nonparametric’’ methods
(Greenberg et al. 1996). We had two motivations for
that letter. The more important reason was that many
of our colleagues have reported difficulties in getting
linkage studies funded—or in getting linkage findings
published–when LOD scores are used to analyze data.
A related impetus for our letter was that there appears
to be widespread ignorance of an extensive literature,
some of which was cited in our letter, supporting the use
of LOD scores. We believe this lack of awareness ac-
counts for the belief of many peer reviewers, of both
grant proposals and manuscripts, that LOD scores rep-
resent an analysis method inferior to or less powerful
than the affecteds-only methods. We tried to address
these issues in our letter, because this incorrect belief not
only has the negative consequences alluded to above but
also runs counter to the practice of good science. We
also hoped that our letter would stimulate open discus-
sion of the mathematical issues involved. In this respect
we were glad to see a further commentary on our letter,
by Kruglyak (1997; also see Farrall [1997] and our re-
sponse [Greenberg et al. 1997]). However, we feel that
it is necessary to focus on some of the points made by
Kruglyak.
We respond to the three major points raised by Dr.
Kruglyak, which concern (1) the use and meaning of the
terms ‘‘nonparametric’’ and ‘‘model free’’; (2) LOD
scores and power; and (3) the role of the true mode of
inheritance in LOD scores and in ‘‘model-free’’ methods.
1. “Nonparametric” and “model free.”—In his com-
ments, Kruglyak (1997, p. 255) gives a strict statistical
definition of ‘‘nonparametric’’ or ‘‘model-free’’ tests as
being those which ‘‘are valid [italics his] regardless of
the true (unknown) genetic parameters, in the standard
sense that they give the correct false-positive rate.’’ He
then reiterates that this property applies to LOD-score
analyses, under the wrong model (‘‘wrod’’ scores [Hodge
and Elston 1994]), just as much as to affected-sib-pair
(ASP), affected-pedigree-member, or nonparametric-
linkage analyses. The fact that, regardless of whether the
assumed model is correct, all of these methods, including
LOD scores, satisfy the standard statistical definition of
a nonparametric test is apparently not widely under-
stood, although it was formally proved by Williamson
and Amos (1990). (Of course, this guarantee of statis-
tical validity holds only for a single LOD score or wrod
analysis, just as it holds only for a single affecteds-only
analysis. If an investigator wants to perform two or more
linkage analyses, whether LOD score or affecteds-only,
allowance must be made for multiple tests. Elsewhere,
we have quantified some of this requirement [Hodge et
al. 1997].) However, ‘‘nonparametric’’ is currently used
by most writers to mean ‘‘does not explicitly state a
genetic model’’ (but see Elston [1997]). This usage is so
ingrained that, subsequently in his letter, Kruglyak him-
self uses ‘‘nonparametric’’ in this ‘‘common’’ way (Krug-
lyak 1997). Thus, this is not merely an issue of termi-
nology. It is important because the current usage of
‘‘nonparametric test’’ hides the fact that the nominal
probability of type I error is asymptotically correct in
all of the analytic methods under discussion, including
LOD scores under the wrong model.
2. LOD scores and power.—In his letter, Kruglyak
(1997, p. 255) concludes that ‘‘the interesting issue in
the design of such [alternative linkage] methods is how
to achieve a minimal loss of power while retaining ro-
bustness to a maximal range of alternatives.’’ We
strongly agree. However, he seems to imply—although
he does not explicitly state—that, in this respect, LOD
scores fare worse than other methods. He says that,
when they use LOD scores, researchers who ‘‘guess
wrong’’ about the genetic model can ‘‘lose big.’’ We,
too, were concerned about this danger, and that concern
provided the impetus for the research cited in our orig-
inal letter, research that showed that this was not a dan-
ger. Kruglyak (1997, p. 255) also says that investigators
can ‘‘fish over all possible models and pay the statistical
price.’’ However, it is not necessary to fish over all pos-
sible models (again, the reasoning and citations are in
our original letter), and our recent work has shown that
comprehensive coverage of models can be had at a mod-
est price in terms of type I error (Hodge et al. 1997).
3. Role of the true mode of inheritance.—Here is
where the terms used in current parlance—
“nonparametric” and “model free”—have proved to be
somewhat misleading. Some colleagues with whom we
have spoken have concluded incorrectly that all statis-
tical properties of these methods are independent of the
